Share
Karl Rotthier
Sterling Pharma Solutions has appointed Karl Rotthier as Chief Executive Officer (CEO), marking a new chapter in the company’s leadership.
Rotthier succeeds Kevin Cook, who has led Sterling since 2013 and is retiring. To ensure a seamless transition, Cook will work closely with Rotthier until 31 October 2025, providing guidance and support during the leadership handover.
Karl Rotthier brings extensive experience in the pharmaceutical and life sciences sector, known for his strategic vision, operational expertise, and ability to drive sustainable growth. His appointment underscores Sterling’s commitment to maintaining its position as a leading provider of integrated pharmaceutical services while continuing to innovate and expand its global footprint.
As CEO, Rotthier will focus on advancing Sterling’s mission of delivering high-quality solutions across drug development, manufacturing, and commercialization. His leadership is expected to strengthen operational efficiencies, foster strategic partnerships, and accelerate growth across existing and new markets.
This appointment reflects Sterling’s focus on continuity, innovation, and strategic execution. With Kevin Cook’s support during the transition, Rotthier is well-positioned to build on the company’s strong foundation, driving long-term success and ensuring Sterling continues to meet the evolving needs of its global client base.
Rotthier’s leadership signals a renewed commitment to operational excellence, client-centric solutions, and strategic growth, as Sterling looks ahead to the next phase of its development in the competitive pharmaceutical services landscape.
